Investor Overview


Corporate Profile

Tocagen is a clinical-stage, cancer-selective gene therapy company developing first-in-class, broadly applicable product candidates designed to activate a patient’s immune system against their own cancer from within. Tocagen is currently studying its lead product candidate, Toca 511 & Toca FC, in a Phase 3 clinical trial for the treatment of patients with recurrent high grade glioma (HGG), a type of brain cancer with limited treatment options. Toca 511 & Toca FC has been granted Breakthrough Therapy Designation for the treatment of patients with recurrent HGG by the FDA, and PRIME (PRIority MEdicines) designation by the European Medicines Agency.
NASDAQ GS TOCA (Common Stock)
$9.13 + 0.61
Stock chart for: TOCA.O.  Currently trading at $9.13 with a 52 week high of $15.80 and a 52 week low of $6.47.
04/25/19 4:00 p.m. ET
Data provided by Nasdaq. Minimum 15 minutes delayed.

Recent News

View All  

Tocagen Appoints Fairooz Kabbinavar, M.D., FACP, as Senior Vice President, Clinical Development

04/15/19

Read More

Tocagen to Present Updated Data from Clinical and Preclinical Studies at Two Scientific Conferences

03/27/19

Read More

Tocagen Reports Fourth Quarter and Full Year 2018 Financial and Business Results

02/27/19

Read More

Recent Presentation

View All  
DateTitle
03/01/19
Download Documentation Tocagen Corporate Presentation – March 1, 2019

Upcoming Events

View All  
There are currently no events scheduled.